<DOC>
	<DOCNO>NCT01214642</DOCNO>
	<brief_summary>This study conduct determine safety LY2523355 treatment advance and/or metastatic cancer ( include Non-Hodgkin 's lymphoma ) .</brief_summary>
	<brief_title>A Dose-Escalation Study Patients With Advanced Cancer</brief_title>
	<detailed_description>This study multi-center , non-randomized , open label , dose-escalation , Phase 1 study intravenous LY2523355 patient advance and/or metastatic cancer ( include non-Hodgkin 's lymphoma ) treatment high priority exists .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Have diagnosis advance and/or metastatic cancer ( solid tumor NonHodgkin 's lymphoma ) refractory standard therapy proven effective therapy exists . Participants enter Part B study must also tumor safely amenable serial biopsy Have presence measurable nonmeasurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) Revised International Working Group Lymphoma Response Criteria Have performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue previous therapy cancer , include chemotherapy , radiotherapy , cancerrelated hormonal therapy , investigational therapy least 28 day ( 6 week mitomycinC nitrosoureas ) prior study enrollment Males females reproductive potential must agree use medically approve contraceptive precaution trial 3 month follow last dose study drug Females child bear potential must negative urine serum pregnancy test less equal 7 day prior first dose study drug Have estimate life expectancy great equal 12 week . Have symptomatic , untreated uncontrolled central nervous system ( CNS ) metastases . Participants treat CNS metastasis eligible provided disease radiographically stable , asymptomatic , currently receive corticosteroid and/or anticonvulsant . Screening asymptomatic participant without history CNS metastasis require Have current acute chronic leukemia Have autologous allogenic bone marrow transplant Females pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>Cancer</keyword>
</DOC>